Biohaven partners with SK Biopharmaceuticals on epilepsy drug in $795M deal
Biohaven has entered a licensing agreement with South Korea's SK Biopharmaceuticals for its epilepsy drug candidate. The deal could be worth up to $795 million, covering global rights to Biohaven's Kv7 ion channel platform. The partnership aims to commercialize the late-stage therapy.
Biohaven’s licensing pact with SK Biopharmaceuticals centers on a late-stage epilepsy therapy built around the Kv7 ion channel platform. Under the agreement, SK Biopharmaceuticals gains global commercialization rights, while Biohaven receives potential payments totaling up to $795 million. The deal underscores growing interest in ion channel modulation as a targeted approach for neurological conditions. Financial terms suggest milestone-based payouts tied to development and sales achievements, though specific breakdowns were not disclosed. The partnership leverages SK’s established presence in Asian markets and Biohaven’s clinical-stage expertise, aiming to accelerate the drug’s path to regulatory approval and eventual launch.
This deal could reshape access to new epilepsy treatments, particularly if the Kv7 platform proves effective for patients with drug-resistant forms of the condition. Clinicians and patient communities may benefit from a broader pipeline, while competitive pricing and global distribution could improve availability in underserved regions. However, the $795 million valuation hinges on successful late-stage trials and regulatory clearance, meaning near-term impact remains uncertain. If approved, the therapy may offer an alternative for those who do not respond to existing antiseizure medications, but affordability and reimbursement will likely determine real-world uptake.